Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $79.24M (cash outflow) rose 203.2% year over year, ahead of the +12.0% change in trailing-twelve-month net income. Sequentially, it rose 19.8% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Net income amounted to 1316.9% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 12 analysts of -$243.23M (+23.1%) for the fiscal year ending Dec 2026, a step up from the -16.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$79.24M+19.8% QoQ
- Last fiscal yearDec 2025
- -$197.53M-16.2% YoY
- LTMMar 2026
- -$250.64M+12.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +203.2% | +18.4% | -184.8 pp |
| 1 year | -16.2% | +23.1% | +39.3 pp |
| 3-year CAGR | -3.0% | -6.5% | -3.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (197.53M) USD
- Year-over-year change
- +16.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (197.53M) | +16.2% |
| FY2024 | 2024-12-31 | (235.76M) | -56.0% |
| FY2023 | 2023-12-31 | (151.09M) | +30.1% |
| FY2022 | 2022-12-31 | (216.21M) | +43.4% |
| FY2021 | 2021-12-31 | (381.85M) | — |
Net Income vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.0% is the 7th highest of 10, against a peer median of +25.8%.
- Over three fiscal years its annual growth of -3.0% compares with a peer median of +38.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.24B CNY | +212.7% | +11.7% | 221.3% |
| LTM Mar 2026 | $608.92M USD | +10.8% | -6.7% | 91.0% | |
| LTM Jun 2026 | $519.41M USD | +25.8% | +38.5% | — | |
| LTM Sep 2026 | $428.73M USD | +40.0% | +40.3% | — | |
| LTM Jun 2026 | $294.37M USD | +23.9% | +86.0% | — | |
| LTM Mar 2026 | $250.64M USD | +12.0% | -3.0% | — | |
| LTM Sep 2026 | $237.46M USD | +56.8% | +65.6% | 3851.1% | |
| LTM Jun 2026 | $226.48M USD | +52.3% | +63.7% | — | |
| LTM Jun 2026 | $188.21M USD | -11.4% | -26.6% | 41.9% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding CNTA) | — | +25.8% | +38.5% | 91.0% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (381.85M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| Deferred Income Tax | 0 | (2.86M) | (26.53M) | 2.65M | 2.51M |
| Stock-Based Compensation | 0 | 24.97M | 29.39M | 33.55M | 30.96M |
| Change in Working Capital | (5.38M) | (2.83M) | (18.86M) | 22.1M | (51.24M) |
| Accounts Receivables | (6.72M) | (11.71M) | (12.09M) | (6.6M) | 2.91M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.35M | (2.72M) | (4.59M) | 2.96M |
| Other Working Capital | 1.34M | 2.53M | (4.04M) | 33.29M | (57.11M) |
| Other Non-Cash Items | 251.06M | (3.75M) | 5.93M | 34.46M | 20.56M |
| Operating Cash Flow | (136.14M) | (200.55M) | (160.34M) | (142.06M) | (193.82M) |
| Capital Expenditures | (185.98K) | (1.14M) | (169K) | (34K) | (371K) |
| Acquisitions (Net) | 63.43M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (264.91M) | (140.53M) | (739.76M) |
| Sales of Investments | 0 | 0 | 138.08M | 171.83M | 321.6M |
| Other Investing Activities | 0 | 206K | 0 | 0 | 0 |
| Investing Cash Flow | 63.25M | (931K) | (127M) | 31.27M | (418.53M) |
| Debt Repayment | 73.64M | 0 | 0 | (762K) | 0 |
| Common Stock Issued | 586.44M | 718K | 20.81M | 359.61M | 296.72M |
| Common Stock Repurchased | (12K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (261K) | 310K | 5.91M | (5.19M) |
| Financing Cash Flow | 660.07M | 457K | 21.12M | 364.75M | 291.53M |
| Effect of Forex Changes | 2.9M | (418K) | 615K | 1.23M | (448K) |
| Net Change in Cash | 590.08M | (201.44M) | (265.61M) | 255.19M | (321.27M) |
| Free Cash Flow | (136.33M) | (201.68M) | (160.51M) | (142.09M) | (194.19M) |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.